



# Jagsonpal Pharmaceuticals Ltd

**Corporate Office:** Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,  
Sector-18, Gurugram -122015, Haryana (India)

**Ph.:** +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

**CIN. :** L74899DL1978PLC009181



March 12, 2026

The Department of Corporate Services- Listing <b>BSE Ltd,</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 <b>Scrip Code: 507789</b>	The Department of Corporate Services- Listing <b>National Stock Exchange of India Ltd</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 <b>Symbol: JAGSNPHARM</b>
---	--

**Subject: Buyback of Securities – Outcome of Board Meeting (Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Outcome of Board Meeting)**

Dear Sir/ Madam,

The Board of Directors of Jagsonpal Pharmaceuticals Limited (the “Company”), at its meeting held today, i.e., March 12, 2026, inter alia considered and approved the proposal for buyback of equity shares of the Company in compliance with Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 (SEBI Buyback Regulations), subject to approval of the shareholders and other applicable statutory approvals, as may be required. The details pertaining to proposed Buyback is as under:

### **Buyback Details**

No. of shares proposed to be bought back	Upto 16,00,000 (16 lakhs) equity shares (representing 2.39% of the paid-up equity capital of the Company)
Buyback price	Rs. 250.00 per equity shares (Rupees Two Hundred and Fifty Only)
Maximum Buyback Offer size	Rs. 40,00,00,000 (Rupees Forty Crores only), representing 18.35% of the paid-up equity share capital and free reserves as per audited financial statements as at March 31, 2025

The Maximum Buyback Offer Size does not include expenses such as brokerage costs, fees, turnover charges, securities transaction tax, goods and services tax (if any), stamp duty, filing fees payable to SEBI, stock exchange charges, advisors’ and legal fees, printing and dispatch expenses, public announcement publication expenses and other incidental and related expenses.

### **Method of Buyback**

The Buyback will be undertaken through the “tender offer” route on a proportionate basis in accordance with the provisions of the SEBI Buyback Regulations



# Jagsonpal Pharmaceuticals Ltd

**Corporate Office:** Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,  
Sector-18, Gurugram -122015, Haryana (India)

**Ph.:** +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

**CIN. :** L74899DL1978PLC009181



## Other details:

- Centrum Capital Limited, a SEBI registered Merchant Banker, has been appointed as the Manager to the Buyback.
- The Board has constituted a “Buyback Committee” and delegated necessary powers to it, including fixing the record date and undertaking actions in relation to the proposed Buyback.
- Mr. Pratham Rawal, Company Secretary & Compliance Officer, has been designated as the Compliance Officer for the Buyback.
- The Promoters/Promoter Group will not be participating in the proposed Buyback.
- Details of Postal ballot for seeking shareholder approval for the proposed Buyback will be intimated separately.

The details as required under LODR Regulations read with SEBI Master Circular No. **HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated July 11, 2013, last updated on January 30, 2026**, are provided in **Annexure A** for proposed buyback.

The Board Meeting commenced at 1: 00 P.M. and concluded at 1:45 P.M.

Thanking you,

Yours faithfully,

For **Jagsonpal Pharmaceuticals Limited**

**Pratham Rawal**

**Company Secretary & Compliance Officer**



# Jagsonpal Pharmaceuticals Ltd

**Corporate Office:** Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,  
Sector-18, Gurugram -122015, Haryana (India)

**Ph.:** +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

**CIN. :** L74899DL1978PLC009181



## Annexure- A

### Disclosure of information in relation to Proposed buyback as required under Regulation 30 of SEBI LODR

Sr. No.	Particulars	Details
1.	Number of securities proposed for the buyback	Buyback of up to <b>16,00,000</b> Equity Shares
2.	Number of securities proposed for the buyback as a percentage of existing paid- up capital	<b>2.39%</b> of the paid-up equity capital
3.	Buyback price	<b>₹250/-</b> (Indian Rupees <b>Two Hundred Fifty</b> only) per Equity Share, payable in cash, for an amount aggregating up to <b>₹40,00,00,000/-</b> (Indian Rupees <b>Forty Crores</b> only)
4.	Actual securities in number and percentage of existing paid- up capital bought back	Buyback of up to <b>16,00,000</b> Equity Shares aggregating up to <b>2.39%</b> of the total number of Equity Shares in the existing total paid-up Equity Share capital of the Company. However, the actual number of Equity Shares and percentage of existing paid-up capital bought back shall be ascertained following completion of the buyback.
5.	Pre & post shareholding pattern	Please refer to <b>Annexure B.</b>



# Jagsonpal Pharmaceuticals Ltd

**Corporate Office:** Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,  
Sector-18, Gurugram -122015, Haryana (India)

**Ph.:** +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

**CIN. :** L74899DL1978PLC009181



## Annexure-B

### Pre buyback and Post- buyback Shareholding pattern of the Company

Category of shareholder	Pre-buyback (as on March 12, 2026)		Post-buyback*	
	No. fully paid up equity shares held	Shareholding as a % of total no. of shares	No. of fully paid-up equity shares held	Shareholding as a % of total no. of shares
(A) Promoter & Promoter Group	4,50,04,785	67.2%	4,50,04,785	68.9%
(B) Public	2,19,57,465	32.8%	2,03,57,465	31.1%
(C) Non-Promoter-Non- Public	-	-	-	-
(C1) Shares underlying DRs	-	-	-	-
(C2) Shares held by Employee Trust	-	-	-	-
Total	6,69,62,250	100.00	6,53,62,250	100

\*Indicative assuming buyback of **16,00,000** equity shares. However, the Post buyback shareholding pattern will change depending on the actual number of Equity Shares bought back.